GRAIL

GRAIL develops blood-based tests for early cancer detection using next-generation sequencing and machine learning. Its flagship product, Galleri, is a multi-cancer early detection test offered through physicians and health systems, with commercialization supported by large population-scale clinical studies. The company was founded in 2016 and is headquartered in Menlo Park, California.